Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CEO Blog: February 2018
Posted by U.S. Stem Cell, Inc
Dear Shareholders and Friends,
Thank you all so much for taking the time to learn more about our recent progress. In this post, we want to take a moment to share key highlights from 2017, as well as update you with new developments for 2018.
A strengthening economy, an increase in marketplace demand as more people learn about stem cell treatments and alternatives to opioids, and an increase in more doctors and physicians advancing their skill sets to include stem cell treatments are all reasons why we are beginning to see steady growth.
We are pleased to announce that our proprietary AdipocellTM stem cell kit has reached 10,000 units in sales — an indication that the marketplace is starting to demand stem cell therapy more readily. Although we reached the goal in January of 2018, much of the effort behind attaining that benchmark was done in 2017, and our hard work is paying off.
We are also proud to announce we have completed more than 10,000 stem cell procedures since 1999 for a variety of indications — including orthopedic, autoimmune, degenerative and neurological diseases. We are pleased to share that, to-date, we have trained more than 700 physicians worldwide on stem cell therapy, and we anticipate that number will only continue to increase.
The FDA’s issuance of guidance documents in November of last year also has also signaled to the marketplace the legitimacy of stem cell therapy as a practice. Because our science is based on the use of a patient’s own (autologous) stem cells, we are confident that the issuance of these guidance documents moves us closer to a time when there will be clear differentiation between treatments that are autologous, versus those that involve the use of donated, off-the-shelf, third-party stem cells that may or may not have been genetically manipulated and clearly require more regulation.
USRM is working with one of the best legal teams based in Washington, D.C., to help communicate with the FDA while preserving the rights of patients to harness their bodies’ own healing potential. We have joined forces with the Academy of Regenerative Practices to ensure that our physicians have a right to practice regenerative medicine with their consenting patients. We are proud sponsors of the upcoming ARP annual conference March 1st – 3rd where our Chief Science Officer Dr. Kristin Comella will be a keynote speaker.
Demand for stem cell therapy is anticipated to be at an all-time high this year, as more patients seek the growing trend of using their own cells to heal various injuries and diseases. As a result, we have expanded our clinic locations to include West Palm Beach. This expansion is timely, given the emerging and explosive demand now coming from patients and the marketplace. We have worked very hard as a team to temper our growth in order to be ready to meet the demands of a growing market at just the right time. We are confident that timing is now.
USRM technologies are now offered in six continents with interest from various countries throughout the world growing. We have experienced a few delays with our facilities opening in Kuwait due to unforeseen regulatory hurdles. These types of challenges are very familiar to us, we know it is part of the landscape and we know how to address them. We will continue to work with our legal team to neutralize these concerns and move forward with bringing stem cell treatments to the patients in the Middle East.
The recent opioid crisis in America means more patients are seeking alternative therapies to pharmaceuticals and surgery for coping with and managing chronic pain. Stem cell therapy may offer new solutions for these patients experiencing systemic diseases, orthopedic conditions, neurological symptoms and other therapies for an aging population. Shape Magazine discusses this subject in their most recent issue, where they mention Dr. Kristin Comella and her work with autologous stem cells. Shape Magazine is the first of many highly-visible mentions where Dr. Comella has been featured, including “The Healing Miracle: The Truth About Stem Cells,” a docuseries that interviews renowned experts in the field of stem cell medicine and explores in-depth the benefits and application of regenerative stem cell therapy. Dr. Comella is featured in Episode five of the docuseries; that interview can be viewed in its entirety here.
Due to the overwhelming response we have had as a result of that docuseries, we were inspired to launch our own live webinar series in order to educate and inform our audience, as well as provide a forum for Q & A on an anonymous platform. “Facts About Stem Cell Therapy,” which had its first live broadcast February 9th, was very well received and had more than 100 participants. Dr. Comella answered questions live for nearly two hours, which is another demonstration of the growing demand for information about this emerging, holistic, regenerative therapy. If you are interested in joining our mailing list to receive notification for our next stem cell webinar, click here.
In honor of Valentine’s Day and the month of love, our second webinar was broadcast live February 17th and featured Dr. Comella and fitness expert and world renown leading biohacker Ben Greenfield. The webinar, which is entitled “Enhancing Sexual Performance with Stem Cell Therapy,” provides the opportunity to learn more about stem cell therapy and enhancing sexual performance. Greenfield, who recently underwent penile enhancement with stem cell therapy, documented his journey in the January issue of Men’s Health magazine. He was successful at increasing both size and rate of performance. To listen to that webinar in its entirety click here.
Our commitment to this emerging science is unwavering and we will continue to expand efforts to help patients maximize their health with this amazing technology. We thank you for your interest and continued support and welcome the chance for an ongoing dialogue to answer any questions you may have.
Warmest regards,
Mike Tomas,
From what I have heard bone marrow is much harder to obtain from a patient and starts out with a lot less cells than adipose tissue.
I wonder if the Mayo is able to use that process for adipose tissue cells? Sounds like it’s just for bone marrow right now. Great advancement though it sounds.
Great day yay! I’m holding my shares for as long as I possibly can. Regenerative medicine and USRM are heating up nicely from what I can see! Retirement stock imo.
$USRM
Great post again A1! I agree and think those kits have huge potential!! Say each clinic uses 5 a day which I’m sure is low and say there is approx 260 working days in the year. They have 287 relationship which have contributed to current kit sales. So 5 kits per day multipled by 260 working days is 1300 Kits a year per relationship/clinic. So 1300 kits per clinic annually times 287 clinics is 373,100 kits annually. Say they sell the kits at 100 bucks each eventually 373100 x 100 = $37,310,000 annually. Now what if each clinic per days uses 20 well then times that by 4 or say when insurance gets involved maybe they will be 500 a kit. Numbers are approx but yes there is crazy potential there!!
We will pick up some investors from this weekend I’m sure. A lot of folks will be chatting it up! I hope some of the very big public speakers there with millions of followers stream it or advertise it on FB.
$USRM
Doubt it. To undervalued. Folks have said the same thing for awhile yet it keeps squeezing up. Accumulation!
A few more US stem cell clinic testimonials. Will churn and continue upwards for a long time with many breakout opportunities. Buy and hold. This is just the beginning. Imo
Donald
Well put and me too. Medical revolution at USRM. A leader!
Retirement stock.
$USRM
Will continue going up for many years to come and have many breakouts. Just the beginning. Do some DD. Great investment imo and others.
$USRM
Crosses coming. Like reallllly sooon! Bullish! Only buy the future of medicine stem cell stock! Chart is screaming breakout!
$USRM
I agree. A few will not hurt the long and strong here. Yes there is big money accumulating. Glad a few others see that too. Been going on for a long time now. They know the game and are doing everything they can to get folks shares. Go USRM!
Go to a three month line chart. Look at Jan 5 and feb 16. Same pattern. Shake and fly north. Watch for a big bounce today imo.
$USRM
Exactly. Folks already know and it’s a simple disclosure thing. Talk about a bunch of misinformation in the article though. We’re used to that around here though.
20 day cross coming then on to the golden cross. Imo
Kris Kross will make you jump jump
I believe Morningstar is wrong. Way to low of market cap for what the company has going for it right now. I bet the offer(s) on the table before were more than 25 mil. I give it a 100-200 mil market cap and that’s where some of the competition is. I highly doubt the company would even sell for that. The upside for this company and stock is to huge. Anyone selling anywhere around these levels will be butthurt! All imo.
Academy of Regenerative Practices
Conference coming up. LOOKS GREAT! I like all the sponsors they have including US STEM CELL CLINIC of course! Great Advertising tool!
USRM CSO to Host Live Stem Cell Info Webinar with World Renowned Biohacker
Posted by U.S. Stem Cell, Inc
‘Discussing Enhancing Sexual Performance with Stem Cell Therapy’ Feb. 17 at Noon
SUNRISE, FL – Feb. 14, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced its Chief Science Officer, Dr. Kristin Comella, will host a live webinar open to the public with Ben Greenfield — a leading biohacker and fitness expert and CEO of health company Kion— who recently had penile stem cell injections to enhance sexual performance.
“Enhancing Sexual Performance with Stem Cell Therapy,” will be a live-streamed discussion and Q & A with Dr. Comella and Greenfield Saturday, Feb. 17, at Noon EST. To participate in the webinar, please register by clicking on the link here: https://attendee.gotowebinar.com/register/7172776642688626689.
Greenfield, a self-professed ‘biohacker’ who recently received stromal vascular fraction treatments (SVF) for erectile enhancement as part of his ongoing exploration of optimal physical performance, including penile enhancement, says as a result of the treatment he has experienced penile enlargement and more frequent erections.
“My drive to discover cutting-edge therapies is what led me to U.S. Stem Cell, and my results certainly convinced me of the validity of this treatment,” said Greenfield. “The opportunity to dictate our own therapies to enhance performance in all arenas of health is an empowering part of physical performance, and it is a demonstration that regenerative medicine is here now.”
“Because so many patients are seeking holistic alternatives to sustain sexual performance, and because it’s Valentine’s Day, we thought it would be the perfect opportunity to discuss the use of autologous stem cells in this arena,” said Dr. Kristin Comella, USRM’s Chief Science Officer. “Ben’s experience and his willingness to be open about sharing his journey will give a lot of people the opportunity to ask questions in an anonymous setting, so that they can learn more about whether the benefits of SVF is right for them.”
SVF involves using USRM’s proprietary AdipocellTM kit to help isolate a patient’s own stem cells from their fat cells. Studies of stromal vascular fractions used in ED therapy are starting to emerge, as is documented in a scientific paper featured in EBioMedicine’s January 2017 issue.
Autologous stem cell treatments harvested from the patient’s own fat could provide healthier alternatives to the use of pharmaceuticals for erectile enhancement and dysfunction (ED) — a worldwide market that is estimated to be more than $4 billion annually and has slowed in growth due to toxic side effects from pharmaceuticals currently on the market, according to a report by Grand View Research published in July 2016. As a result, more men and women are seeking out stem cell therapy to enhance sexual performance, which to date has yielded more than 35 scientific studies about stem cell therapy and sexual enhancement.
“Enhancing Sexual Performance with Stem Cells,” is the second in a series of webinars by USRM and Dr. Comella, dedicated to educating, informing and demystifying the public about the practice of regenerative stem cell therapy. The first webinar, “Facts About Stem Cell Therapy,” which was broadcast live last Friday, can be accessed as a playback here: (PLS. INSERT LINK).
Dr. Comella, who has more than 20+ years’ experience and is one of the world’s leading stem cell scientists, is also featured in the recent Jeff Hays docuseries “The Healing Miracle: The Truth About Stem Cells.” (Click here to view Dr. Comella’s interview from THM in its entirety.) It was her participation in the docuseries that inspired her to launch the webinar series.
Greenfield, who was voted in 2013 and 2014 as one of the world’s top 100 most influential people in health and fitness by Greatist, coaches top CEO’s, chefs, biohackers, endurance competitors, and professional athletes from the UFC, NHL, NBA, NFL and beyond – all while advising and investing in top companies in the health, fitness and nutrition industries. He was voted in 2008 as Personal Trainer of the Year by the National Strength and Conditioning Association (NSCA), and is a regular contributor to Huffington Post. He is also the CEO of Kion Health and hosts the highly popular Ben Greenfield Fitness podcast, one of the top-ranked health and fitness podcasts in iTunes. He has a bachelor’s degree and master’s degree from University of Idaho in sports science and exercise physiology and personal training, plus strength and conditioning certifications from the NSCA.
USRM has been involved in more than 10,000 stem cell procedures in the past 19 years for a variety of indications including orthopedic, autoimmune, degenerative and neurological diseases. USRM also trains and certifies physicians in stem cell therapy — to date, more than 700+ physicians worldwide — and has engaged with more than 287 clinics. Dr. Comella is well published in the scientific literature and has been recognized by her peers as an innovator and world leader in the development and clinical practice of stem cell products and therapies. She has also been instrumental in developing and bringing to market USRM’s AdipocellTM, a stem cell kit which enables physicians to separate potent stem cells from a patient’s own fat cells, which are harvested and reinserted in a minimally invasive, two-hour procedure without general anesthesia.
U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM , as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics. To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world.
Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.
News Releases
USRM CSO to Host Live Stem Cell Info Webinar with World Renowned Biohacker
Posted by U.S. Stem Cell, Inc
‘Discussing Enhancing Sexual Performance with Stem Cell Therapy’ Feb. 17 at Noon
SUNRISE, FL – Feb. 14, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced its Chief Science Officer, Dr. Kristin Comella, will host a live webinar open to the public with Ben Greenfield — a leading biohacker and fitness expert and CEO of health company Kion— who recently had penile stem cell injections to enhance sexual performance.
“Enhancing Sexual Performance with Stem Cell Therapy,” will be a live-streamed discussion and Q & A with Dr. Comella and Greenfield Saturday, Feb. 17, at Noon EST. To participate in the webinar, please register by clicking on the link here: https://attendee.gotowebinar.com/register/7172776642688626689.
Greenfield, a self-professed ‘biohacker’ who recently received stromal vascular fraction treatments (SVF) for erectile enhancement as part of his ongoing exploration of optimal physical performance, including penile enhancement, says as a result of the treatment he has experienced penile enlargement and more frequent erections.
“My drive to discover cutting-edge therapies is what led me to U.S. Stem Cell, and my results certainly convinced me of the validity of this treatment,” said Greenfield. “The opportunity to dictate our own therapies to enhance performance in all arenas of health is an empowering part of physical performance, and it is a demonstration that regenerative medicine is here now.”
“Because so many patients are seeking holistic alternatives to sustain sexual performance, and because it’s Valentine’s Day, we thought it would be the perfect opportunity to discuss the use of autologous stem cells in this arena,” said Dr. Kristin Comella, USRM’s Chief Science Officer. “Ben’s experience and his willingness to be open about sharing his journey will give a lot of people the opportunity to ask questions in an anonymous setting, so that they can learn more about whether the benefits of SVF is right for them.”
SVF involves using USRM’s proprietary AdipocellTM kit to help isolate a patient’s own stem cells from their fat cells. Studies of stromal vascular fractions used in ED therapy are starting to emerge, as is documented in a scientific paper featured in EBioMedicine’s January 2017 issue.
Autologous stem cell treatments harvested from the patient’s own fat could provide healthier alternatives to the use of pharmaceuticals for erectile enhancement and dysfunction (ED) — a worldwide market that is estimated to be more than $4 billion annually and has slowed in growth due to toxic side effects from pharmaceuticals currently on the market, according to a report by Grand View Research published in July 2016. As a result, more men and women are seeking out stem cell therapy to enhance sexual performance, which to date has yielded more than 35 scientific studies about stem cell therapy and sexual enhancement.
“Enhancing Sexual Performance with Stem Cells,” is the second in a series of webinars by USRM and Dr. Comella, dedicated to educating, informing and demystifying the public about the practice of regenerative stem cell therapy. The first webinar, “Facts About Stem Cell Therapy,” which was broadcast live last Friday, can be accessed as a playback here: (PLS. INSERT LINK).
Dr. Comella, who has more than 20+ years’ experience and is one of the world’s leading stem cell scientists, is also featured in the recent Jeff Hays docuseries “The Healing Miracle: The Truth About Stem Cells.” (Click here to view Dr. Comella’s interview from THM in its entirety.) It was her participation in the docuseries that inspired her to launch the webinar series.
Greenfield, who was voted in 2013 and 2014 as one of the world’s top 100 most influential people in health and fitness by Greatist, coaches top CEO’s, chefs, biohackers, endurance competitors, and professional athletes from the UFC, NHL, NBA, NFL and beyond – all while advising and investing in top companies in the health, fitness and nutrition industries. He was voted in 2008 as Personal Trainer of the Year by the National Strength and Conditioning Association (NSCA), and is a regular contributor to Huffington Post. He is also the CEO of Kion Health and hosts the highly popular Ben Greenfield Fitness podcast, one of the top-ranked health and fitness podcasts in iTunes. He has a bachelor’s degree and master’s degree from University of Idaho in sports science and exercise physiology and personal training, plus strength and conditioning certifications from the NSCA.
USRM has been involved in more than 10,000 stem cell procedures in the past 19 years for a variety of indications including orthopedic, autoimmune, degenerative and neurological diseases. USRM also trains and certifies physicians in stem cell therapy — to date, more than 700+ physicians worldwide — and has engaged with more than 287 clinics. Dr. Comella is well published in the scientific literature and has been recognized by her peers as an innovator and world leader in the development and clinical practice of stem cell products and therapies. She has also been instrumental in developing and bringing to market USRM’s AdipocellTM, a stem cell kit which enables physicians to separate potent stem cells from a patient’s own fat cells, which are harvested and reinserted in a minimally invasive, two-hour procedure without general anesthesia.
U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM , as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics. To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world.
Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.
News Releases
To thin. Not enough sellers. Must raise prices again! :)
$USRM
Demand will skyrocket! Stem cell revolution will bring the news at it will be huge! Being built now and they will come! ;) Glad I’m checked in.
$USRM
Like the green doji. $USRM
Yeah I told maybe 6 and half bought some. We’re golden you’re golden USRM is golden! Cheers
Oh yeah has been. 5 mil volume pushes it up nicely. Had a few of those days the last few months. The other day I think it went up like 8% on just under 2 mil. Folks tucking this one away. Wait until we get a few big volume days. There will be no more holding this back. Imo
$USRM
30 day shows classic cup and handle imo. Golden Cross coming with the 20 and 50 creepin north slowly. Accumulation through the roof and we can all see that it’s being held down with little tiny sells in order to do so. Going Up! Way Undervalued!
Imo
$USRM
Yup I agree the numbers are going to be huge. All this is common sense like golden minded stated. It’s kind of funny..folks are such procrastinators. Watch what happens when the numbers start coming in and regenerative medicine starts really gaining momo. This is the actual time to be loading. All imo and others.
$USRM
Huge Buy Zone....Golden across Coming! A stem company that’s rapidly growing and the pps is under .05 with a market cap around 15 mil..LOL!!! USRM is a leader and it will be huge! Don’t give away your shares for peanuts! Buy and hold. Easy
$USRM
Well at least Sessions did one thing right. :p..Guidelines aren’t the law!
More clinics are Coming per Comella and to me that tells the story!
Buy em up about to explode!
$USRM
I was looking for an article on that and couldn’t find one. Thank you that’s fantastic!
$USRM
Sellers will regret. Stair step and breakout. Way Undervalued! Buy em up. Imo
$USRM
Nope. Misinformation!
MORE NEWS!!!
USRM Successfully Launches Stem Cell Webinar Series
Open to Global Participation, More than 100 Attendees in First Q & A
(PRNewsfoto/U.S. Stem Cell, Inc.)
NEWS PROVIDED BY
U.S. Stem Cell, Inc.
08:30 ET
SUNRISE, Fla., Feb. 12, 2018 /PRNewswire/ -- Dr. Kristin Comella, Chief Science Officer of U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced the successful launch of an open, livestream webinar series designed to inform and educate the public on the benefits and applications of stem cell therapy.
"Facts About Stem Cell Therapy," which had its first live broadcast last Friday and includes a question & answer session from more than 100 patients and physicians around the world, continued for nearly two hours while live streamers posted questions to Dr. Comella about the application of autologous stem cells therapy. Such a strong, positive response demonstrates the growing demand for information about this emerging, holistic, regenerative therapy.
Playback of the webinar can be accessed here:
http://www.brainshark.com/Stemlogix/vu?pi=zHEz136Dfmz5OLvz0.
Dr. Comella will be hosting a second livestream webinar Saturday, Feb. 17, at 12 noon EST (Click here to register). In honor of Valentine's Day and the month of love, her featured guest will be fitness expert Ben Greenfield, who recently underwent stem cell therapy for erectile enhancement -- a multi-million-dollar industry that is increasing in patient population but is underserved, mainly due to side effects associated with erectile dysfunction pharmaceuticals currently on the market.
"The webinar platform gives us the perfect opportunity to make the concept of autologous stem cell therapy accessible to the world," said Dr. Comella. "It also enables audience participation in a manner that allows for privacy. I read the questions to the audience, so we maintain privacy from the inquisitor while simultaneously providing the opportunity for a comprehensive teaching moment, even in playback. It's a perfect way to help people learn more about this incredible form of healing."
Dr. Comella, who has more than 20+ years' experience and is one of the world's leading stem cell scientists, is also featured in the recent Jeff Hays docuseries "The Healing Miracle: The Truth About Stem Cells." (Click here to view Dr. Comella's interview from THM in its entirety.) It was her participation in the docuseries that inspired her to launch the webinar series.
"Dr. Comella is a natural -- her passion is contagious and her expertise in stem cell therapy is unparalleled," said Mike Tomas, Chief Executive Officer of U.S. Stem Cell, Inc. "Because demand has been so strong at our clinics, as more and more people are learning about stem cell therapy as an alternative to pain management, the webinar format gives us the opportunity to reach more people faster, and to meet the demand for more specific information in a really efficient and effective way."
USRM has been involved in more than 10,000 stem cell procedures in the past 19 years for a variety of indications including orthopedic, autoimmune, degenerative and neurological diseases. USRM also trains and certifies physicians in stem cell therapy -- to date, more than 700+ physicians worldwide -- and has engaged with more than 287 clinics. Dr. Comella is well published in the scientific literature and has been recognized by her peers as an innovator and world leader in the development and clinical practice of stem cell products and therapies. She has also been instrumental in developing and bringing to market USRM's AdipocellTM, a stem cell kit which enables physicians to separate potent stem cells from a patient's own fat cells, which are harvested and reinserted in a minimally invasive, two-hour procedure without general anesthesia.
U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM, as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics. To management's knowledge, USRM has completed more clinical treatments than any other stem cell company in the world.
Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "plan", "expect", "believe", "anticipate", "intend", "could", "would", "estimate", or "continue", or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company's business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.
Media Contact: U.S. Stem Cell, Inc.
Phone: 954.835.1500
Email: usstemcell@us-stemcell.com
SOURCE U.S. Stem Cell, Inc.
Related Links
http://us-stemcell.com
USRM Seeing Explosive Increase in Demand for Stem Cell Therapy
Posted by U.S. Stem Cell, Inc
Failure of Opioids & Economic Growth Driving Force,
CSO to Host Live Info Webinar
SUNRISE, FL – Feb. 6, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced it is experiencing explosive demand for stem cell treatments at its clinics — a trend that is reflected in the 106% increase in revenues during the 3rd Q and is continuing as a result of rapidly increasing demand from the marketplace.
As a result, USRM Chief Science Officer Dr. Kristin Comella, who is featured in the docuseries, “The Healing Miracle: The Truth About Stem Cells,” will be hosting a live webinar Friday, Feb. 9, to help answer questions about stem cell therapy and treatments.
“Our phones are ringing off the hook,” said Dr. Comella. “Public demand is ramping up quickly, as Americans invest in educating themselves on stem cell therapy and alternatives to opioid protocols for chronic pain. Moreover, because stem cell therapy is an out-of-pocket expense, improved economic indicators are giving Americans more money in their pockets for discretionary spending, which is increasing opportunity for stem cell treatments,” said Dr. Comella.
Total revenue for 2017, which will be announced in mid March when the company files its 10k, is expected to increase from 2016.
“We have seen significant revenue increases for the past six straight quarters and market demand is starting to drive revenue even further” said Mike Tomas, Chief Executive Officer of U.S. Stem Cell, Inc. “We look forward to sharing news of our continued growth and are pleased to see 2018 is starting off so well with the recent milestone of reaching 10,000 units sold for our proprietary AdipocellTM product,” said Tomas. “We believe this is an indicator of continued growth to come.”
Dr. Comella, who has more than 20+ years’ experience and is one of the world’s leading stem cell scientists, can be seen in The Healing Miracle docuseries here. To view Dr. Comella’s interview online, click the link and fill out the information, which will provide complimentary access.
To access Dr. Comella’s live webinar this Friday, Feb. 9, at Noon EST, click here to register or join. Details of the webinar, along with a playback link after it is broadcast, will also be posted on the company’s website and its Facebook page (https://www.facebook.com/USStemCellInc/).
USRM has been involved in more than 10,000 stem cell procedures since 1999 for a variety of indications including orthopedic, autoimmune, degenerative and neurological diseases. USRM also trains and certifies physicians in stem cell therapy — to date, more than 700+ physicians worldwide — and has engaged with more than 287 clinics. Dr. Comella is well published in the scientific literature and has been recognized by her peers as an innovator and world leader in the development and clinical practice of stem cell products and therapies. She has also been instrumental in developing and bringing to market USRM’s AdipocellTM, a stem cell kit which enables physicians to separate potent stem cells from a patient’s own fat cells, which are harvested and reinserted in a minimally invasive, two-hour procedure without general anesthesia.
U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM , as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics. To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world in the past 20 years; has more than 287 clinics using its proprietary technology and has certified more than 700 physicians and veterinarians in autologous stem cell therapy worldwide.
Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.
News Releases
http://us-stemcell.com/usrm-seeing-explosive-increase-in-demand-for-stem-cell-therapy/
Agree!! We have a great core group of investors here. Let’s ride this baby up to Dollars! Stem Cells treatment will become mainstream and Wall Steet will grab this puppy! That’s what I’m waiting for! All imo.
$USRM
Thx for sharing! Tell them Jason Taylor is a shareholder if you haven’t already. They may think that’s interesting.
Jason Taylor mentioned in a blog last Aug:
http://us-stemcell.com/historic-quarter-for-ussc/
I’m sure you were here and saw this Sports Illustrated article but just in case.
http://amp.si.com/nfl/2017/09/26/dr-james-andrews-institute-stem-cells-sports-medicine-stroke-bart-starr
Sure sounds like it will change sports to me! And...
Per Brilliant Dr. Murphy “stem cells will change medicine like antibiotics did”!
Going to have a snowball effect as Wolf mentioned!
All imo and others ;)
$USRM
#StemCellsKickAss
Great Post X! The word is starting to spread. An amazing and unstoppable medical revolution is about to happen! A LEADER! $$USRM
Here are a few more eye opening articles that just came out!
Functioning human mini-kidney grown from stem cells in mice for first time
http://www.independent.co.uk/news/health/human-kidney-grown-mouse-stem-cells-urine-medical-first-scientists-functioning-tissue-cells-a8202856.html
Stem cell divisions in the adult brain seen for the first time
https://www.sciencedaily.com/releases/2018/02/180208141315.htm
Umbilical Cord Blood Stem Cells May Improve Symptoms in Children with Autism
https://medicalresearch.com/mental-health-research/autism/umbilical-cord-blood-stem-cells-may-improve-symptoms-in-children-with-autism/39943/
Great info.! Could of said spoiler alert...ha jk :) thanks for putting your listening ears on!
#ComellaRocks
Wall Street just called! Weeee!!!
Medical Revolution @ USRM they say! HOLY BULLISH!
Not many to choose from really and with momo. Possible. Fingers crossed. $USRM
That 20 and 50 are sure creepin’ close to that 200 though. ;)